Allogeneic Adipose-derived Mesenchymal Stem Cells clinical trials
How each study uses Allogeneic Adipose-derived Mesenchymal Stem Cells is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Allogeneic Adipose-derived Mesenchymal Stem Cells studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2021 (5)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 6
Anterogen Co., Ltd. (8) · Sorrento Therapeutics, Inc. (6) · Stempeutics Research Pvt Ltd (2) · Mya Schiess (1) · LaTonya J. Hickson (1) · Rigshospitalet, Denmark (1) · The University of Texas Health Science Center, Houston (1) · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Allogeneic Adipose-derived Mesenchymal Stem Cells.
- Mar 2027Allogeneic Use of Expanded Mesenchymal Stem Cells Derived From Adipose Tissue (HC106), Female Urinary Incontinence Women Over 50 Years OldPhase 1 · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Jul 2027Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing CraniotomyPhase 1 · Mayo Clinic
Studies
Open first, then newest update. How each study uses Allogeneic Adipose-derived Mesenchymal Stem Cells is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 22
- Allogeneic Use of Expanded Mesenchymal Stem Cells Derived From Adipose Tissue (HC106), Female Urinary Incontinence Women Over 50 Years OldRecruitingPhase 1Instituto de Investigación Sanitaria de la Fundación Jiménez DíazNCT06738576Written as allogeneic mesenchymal stem cellsHow we know
- Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing CraniotomyRecruitingPhase 1Mayo ClinicNCT05789394Written as Allogeneic Adipose-derived Mesenchymal Stem CellsHow we know
- Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot UlcersRecruitingPhase 2Anterogen Co., Ltd.NCT04497805Written as ALLO-ASC-SHEETHow we know
- Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's DiseaseCompletedPhase 2Mya SchiessNCT04506073Written as Mesenchymal Stem CellsHow we know
- Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.CompletedPhase 3Anterogen Co., Ltd.NCT04569409Written as ALLO-ASC-DFUHow we know
- Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot UlcersCompletedPhase 2Anterogen Co., Ltd.NCT03754465Written as ALLO-ASC-DFUHow we know
- Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney DiseaseCompletedPhase 1LaTonya J. HicksonNCT05362786Written as Allogeneic adipose-derived mesenchymal stem cells (MSC)How we know
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary CompromiseWithdrawnPhase 2Sorrento Therapeutics, Inc.NCT04992247Written as COVI-MSCHow we know
- Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.CompletedPhase 3Anterogen Co., Ltd.NCT03370874Written as ALLO-ASC-DFUHow we know
- A Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury SubjectsCompletedPhase 2Anterogen Co., Ltd.NCT02619851Written as ALLO-ASC-DFUHow we know
- Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's SyndromeCompletedPhase 2Rigshospitalet, DenmarkNCT04615455Written as ASCsHow we know
- Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory DistressTerminatedPhase 2Sorrento Therapeutics, Inc.NCT04903327Written as COVI-MSCHow we know
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory DistressStatus unknownPhase 2Sorrento Therapeutics, Inc.NCT04905836Written as COVI-MSCHow we know
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress SyndromeWithdrawnPhase 2Sorrento Therapeutics, Inc.NCT04909879Written as COVI-MSCHow we know
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary CompromiseWithdrawnPhase 2Sorrento Therapeutics, Inc.NCT04909892Written as COVI-MSCHow we know
- Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory DistressWithdrawnPhase 2Sorrento Therapeutics, Inc.NCT04728698Written as COVI-MSCHow we know
- Stem Cell Injection in Cancer SurvivorsCompletedPhase 1The University of Texas Health Science Center, HoustonNCT02509156Written as Allo-MSCsHow we know
- Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot UlcersCompletedPhase 2Anterogen Co., Ltd.NCT02619877Written as ALLO-ASC-DFUHow we know
- Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver CirrhosisCompletedPhase 2Stempeutics Research Pvt LtdNCT01591200Written as Allogeneic Mesenchymal Stem CellsHow we know
- A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers DiseaseCompletedPhase 2Stempeutics Research Pvt LtdNCT01484574Written as Allogeneic Mesenchymal Stem CellsHow we know
See all 22 studies that test Allogeneic Adipose-derived Mesenchymal Stem Cells →